Viemed Healthcare (VMD) Fundamental Analysis: Revenue, Earnings & Valuation

7.28 / 10

Outperform

Fundamental analysis rates VMD as Outperform with a 7.28 score. Key strengths include high YoY profit growth (34.6%), cash‑up (‑0.34) and earnings per share gains (>31%). Weak points are low Asset‑MV (‑0.55) and modest PB‑ROE, yet revenue‑MV and cash‑flow metrics boost the outlook.

Analysis Checks(7/10)

Revenue-MV

Value0.41

Score3/3

Weight32.63%

1M Return7.98%

Net cash flow from operating activities per share (YoY growth rate %)

Value36.71

Score3/3

Weight22.34%

1M Return5.35%

PB-ROE

Value0.41

Score0/3

Weight-3.52%

1M Return-1.30%

Basic earnings per share (YoY growth rate %)

Value31.03

Score2/3

Weight5.94%

1M Return1.70%

Total profit (YoY growth rate %)

Value34.61

Score2/3

Weight6.95%

1M Return1.87%

Net cash flow from operating activities (YoY growth rate %)

Value32.81

Score3/3

Weight22.77%

1M Return5.57%

Cash-UP

Value-0.34

Score2/3

Weight6.79%

1M Return1.89%

Diluted earnings per share (YoY growth rate %)

Value32.14

Score2/3

Weight4.35%

1M Return1.25%

Asset-MV

Value-0.55

Score0/3

Weight-3.10%

1M Return-0.96%

Cash-MV

Value0.44

Score1/3

Weight4.85%

1M Return1.42%

Is VMD undervalued or overvalued?

VMD scores 7.28/10 on fundamentals and holds a Discounted valuation at present. Backed by its 10.79% ROE, 5.69% net margin, 24.79 P/E ratio, 2.58 P/B ratio, and 31.03% earnings growth, these metrics solidify its Outperform investment rating.